It appears you have not yet Signed Up with our community. To Sign Up for free, please click here....



Message Board
THIS MESSAGE BOARD IS NO LONGER ACTIVE. TO SEE OUR ACTIVE MESSAGE BOARDS, PLEASE GO HERE





Message
Posted by Kathy on April 27, 2000 at 14:05:04:

Please read the below information on Tall-104. Initial trials have been
extremely promising for an actual CURE for several cancers and good
remissions for others. However, a drug manufacturer is needed to produce
these cells so that they will be avilable for cancer trials and treatment
for both animals and people and so far none have stepped up to the plate.
Time is passing and the cancer is continuing to grow and kill its victims.
Your e-mail indicating your desire to get this treatment for cancer victims
will be a BIG help in having a drug manufacturer spend their time and money
to produce this protocol.

Please help by forwarding an e-mail saying you want Tall-104 on the market.
Send to Dr. Santoli at: santoli@wistar.upenn.edu or FAX: (215)573-7919


Please send this e-mail to every cancer dog or cat owner you know as well as
to every vet and person with cancer. Ask them to e-mail Dr. Santoli
indicating their desire to have this protocol made available.

Thank you for helping those you love and yourselves.

Canines In Crisis
www.crosswinds.net/~k9cancerinfo

Tall-104

The San Diego Union-Tribune
Wed, Jan 14 1998

Beginning three years ago, researchers from the Wistar Institute in
Philadelphia gave an experimental therapy to 19 dogs dying of cancer.

The pets were considered too sick to derive much benefit, but their
reactions would show whether the therapy, called TALL-104, had toxic side
effects. If it was safe, the next step would be proving it worked. To the
researchers' astonishment, six of the 19 dogs temporarily went into
remission - and one was completely cured. There were no serious side
effects. And the therapy not only attacked cancerous cells, but stimulated
some of the dogs' immune systems to take over the attack. "We really did not
expect much, so having seven responses was a remarkable thing," said Wistar
immunologist Daniela Santoli, research team leader. TALL-104 has proven to
be so effective in treating cancer in dogs and cats that Santoli and her
colleague plan to seek federal marketing approval of the therapy for
veterinary use. It also has begun human testing. A trial at Children's
Hospital of Philadelphia is enrolling children with advanced leukemia,
lymphoma, and bone, brain or kidney cancer; another trial at the Hospital of
the University of Pennsylvania is enrolling women with advanced, spreading
breast cancer.

The new approach relies on T-cells, human immune system cells that are
programmed by the body to destroy foreign invaders and cancerous cells. Ten
years ago, Santoli was studying T-cells taken from a child with acute
lymphoblastic leukemia, a blood cancer in which immature T-cells multiply
uncontrollably. Under the microscope, Santoli saw that the child's T-cells
were filled with toxic proteins.

She wondered whether these malignant immune cells could be harnessed to kill
other malignant cells. She began growing batches of the child's cells,
dubbed TALL for T-cell acute lymphoblastic leukemia, and treating mice. TALL
cells were prevented from causing leukemia in the mice by bombarding the
cells with radiation. Surprisingly, the cells did not trigger significant
rejection, even when testing moved from mice to dogs and cats, animals with
immune systems similar to those of humans. TALL-104 had no serious side
effects in animals. It apparently attacks only cancer cells. Equally
important, TALL-104 somehow alerts the patient's immune system to attack
lingering cancer cells, thus preventing cancer from recurring.

TALL-104 is currently being tested on 45 dogs and 16 cats with less advanced
cancers. All are now in remission, and many are beyond the point when they
would be expected to suffer a recurrence of cancer, Santoli said. It will
take at least another year to obtain federal approval for TALL-104, and to
find a biotechnology company to mass produce the cells. Santoli said her lab
spends about $80 to
produce a single dose. TALL-104 therapy for humans is farther off -- if the
trials go well. Phased testing to evaluate the toxicity, dosing and
effectiveness in humans of a new drug normally takes at least five years.
But most drugs that are promising in animals don't pan out in humans.

So far, only four children and a few women have begun receiving TALL-104.
Their doses are lower than those found to be effective in animals, because
early testing is designed to evaluate toxicity and dosing regimens. "This is
very novel and it is met with tremendous skepticism" by scientists, said
pediatric oncologist Beverly L. Lange, who is leading the trial at
Children's Hospital of Philadelphia. "But it's a reasonable thing to try."

(Copyright 1998)
_______________________________________________________________________
FOR IMMEDIATE RELEASE: 10 MAY 1999

Contact: Diana Cutshall
dcutshall@wistar.upenn.edu
215-898-3716
Wistar Institute

Wistar Scientist Awarded American Cancer
Society Grant For Research On Tumor Killing
Cells

Philadelphia-- Daniela Santoli, Ph.D., a professor in The Wistar
Institute's Tumor Immunology Program, has been awarded a $300,000 two-year
grant from the American Cancer Society for a Phase I/II trial of TALL-104
cells in patients with metastatic melanoma.

TALL-104 is a "killer" cell line derived from the cells of a child
with a rare form of T-cell leukemia. Dr. Santoli has found that TALL-104
cells can recognize and selectively kill malignant cells. Her research team
has used TALL-104 cells to treat pet dogs and cats with various terminal
cancers that were unresponsive to conventional therapy. In many of these
companion animals, the TALL-104 cells caused complete, long-lasting
remissions.

Phase I clinical trials of TALL-104, which tested the safety of the
treatment on humans and established safe dosage ranges for further efficacy
trials, were conducted on children with advanced cancers and women with
metastatic breast cancer. In these trials, no toxicity was shown up to the
planned maximum dose. With the recently awarded American Cancer Society
funds, Dr. Santoli and her clinical
collaborator, Dr. Lynn Schuchter at the Cancer Center of the Hospital of the
University of Pennsylvania, will focus on the development of a TALL-104
regimen that will be effective and safe in melanoma patients with metastatic
disease. These trials are not expected to start until later this year.

The American Cancer Society is the nationwide, community-based
voluntary health organization dedicated to eliminating cancer as a major
health problem by preventing cancer, saving lives and diminishing suffering
from cancer through research, education, advocacy and service. Last year,
the American Cancer Society contributed $93.3 million to research facilities
throughout the country.

The Wistar Institute, established in 1892, was the first independent
medical research facility in the country. For more than 100 years, Wistar
scientists have been making history and improving world health through their
development of vaccines for diseases that include rabies, German measles,
infantile gastroenteritis (rotavirus), and cytomegalovirus; discovery of
molecules like interleukin-12, which are helping the immune system fight
bacteria, parasites, viruses and cancer; and location of genes that
contribute to the development of diseases like breast, lung and prostate
cancer. Wistar is a National Cancer Institute Cancer Center.
____________________________________________________________________________
________

Follow Ups

All times are GMT -7. The time now is 02:44 PM.



Site owned and operated by HealthBoards.comô
Terms of Use © 1998-2014 HealthBoards.comô All rights reserved.
Do not copy or redistribute in any form!